Skip to content

Search

Impact of an evidence-based sepsis pathway on paediatric hospital clinical practice: A quality improvement study

To assess the impact of implementing a sepsis pathway and education program on key sepsis outcomes and performance targets in a tertiary paediatric hospital.

Nirsevimab immunisation of infants and respiratory syncytial virus (RSV)-associated hospitalisations, Western Australia, 2024: a population-based analysis

Christopher Peter Hannah Blyth Richmond Moore MBBS (Hons) DCH FRACP FRCPA PhD MBBS MRCP(UK) FRACP OAM BSc (Hons) GradDipClinEpi PhD Centre Head,

Prospective longitudinal study of respiratory syncytial virus and other respiratory viruses in children <5 years in community settings in metropolitan western Australia: the PATROL study

Respiratory syncytial virus (RSV) is a significant cause of respiratory infections in young children. Since 2021, RSV has been a notifiable disease in Australia. However, current surveillance systems focus on hospitalised RSV, with limited surveillance at a community level through primary care clinics. This approach only captures RSV requiring hospitalisation. Less severe illnesses, while not captured, may have significant social and economic impacts including the associated cost of care and absenteeism. The aim of this study is to establish an understanding of the broader burden of RSV in young children in a community setting.

The impact of a vancomycin intervention on vancomycin-associated nephrotoxicity in children: a quality improvement initiative

Vancomycin is first-line treatment for methicillin-resistant Staphylococcus aureus infections. However, despite guideline recommendations, there is no evidence that targeting vancomycin trough concentrations of ≥15 mg/L in children confers clinical benefit and is associated with vancomycin-associated nephrotoxicity. 

Model-informed precision dosing of vancomycin in children 3 months to 18 years of age using Australia-wide data

Vancomycin is used to treat serious gram-positive infections in children; however, effective dosing information for those aged 3 months to 18 years is limited. We aimed to determine an optimized dosing strategy for this age group.

Delayed diagnosis is associated with complications following invasive meningococcal disease in Australian adolescents and young adults

This study described the presenting features, initial assessment, hospital care, and complications at discharge among Australian adolescents and young adults with Invasive meningococcal disease.

Long-term outcomes of childhood encephalitis in Australia: burden and predictors from the Australian childhood encephalitis (ACE) prospective multicentre cohort

Encephalitis is inflammation of the brain parenchyma with heterogenous aetiology and presentation. In children, it often leads to short-term residual neurological deficits, however clinical predictors of adverse long-term outcome are not fully understood.

Early Childhood Education and Care and Developmental Vulnerability at School Entry

Early childhood education and care (ECEC) is widely recognized for supporting children's development and school readiness; however, evidence from Western Australia remains limited.

Invasive mould infection in children – advances made or obstacles remaining?

Invasive mould infection (IMI) is a major cause of morbidity and mortality in immunocompromised children. Outcomes for paediatric patients with IMI remain poor, due in part to the limitations of available diagnostic tools and therapeutic agents.

Emerging elements of paediatric post-sepsis care programs: A scoping review

Sepsis is a significant cause of mortality for children in Australia, particularly affecting young children, those with pre-existing health conditions and Aboriginal and Torres Strait Islander populations. The transition from hospital to home can be challenging for survivors, often leaving long-term impacts unaddressed.